NextCure/$NXTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NextCure
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Ticker
$NXTC
Sector
Primary listing
Employees
40
Headquarters
Website
NextCure Metrics
BasicAdvanced
$7.9m
-
-$15.32
1.30
-
Price and volume
Market cap
$7.9m
Beta
1.3
52-week high
$15.74
52-week low
$1.78
Average daily volume
115k
Financial strength
Current ratio
4.606
Quick ratio
4.418
Long term debt to equity
14.519
Total debt to equity
18.39
Profitability
EBITDA (TTM)
-54.285
Management effectiveness
Return on assets (TTM)
-66.71%
Return on equity (TTM)
-132.40%
Valuation
Price to book
0.3
Price to tangible book (TTM)
0.3
Price to free cash flow (TTM)
-0.157
Free cash flow yield (TTM)
-636.62%
Free cash flow per share (TTM)
-14.005
Growth
Earnings per share change (TTM)
-27.86%
3-year earnings per share growth (CAGR)
-20.43%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs